NCT00246207View on ClinicalTrials.gov

CONCERTA (OROS Methylphenidate Hydrochloride) for the Treatment of Attention Deficit Hyperactivity Disorder in Adults

PHASE3CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

March 31, 2005

Study Completion Date

December 31, 2005

Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
DRUG

CONCERTA (OROS methylphenidate hydrochloride)

All Listed Sponsors
lead

Janssen-Ortho Inc., Canada

INDUSTRY

NCT00246207 - CONCERTA (OROS Methylphenidate Hydrochloride) for the Treatment of Attention Deficit Hyperactivity Disorder in Adults | Biotech Hunter | Biotech Hunter